Pulmonary Alveolar Proteinosis

 

 Buy Article Permissions and Reprints

Abstract

Pulmonary alveolar proteinosis (PAP) is a rare disorder characterized by the accumulation of surfactant lipids and protein in the alveolar spaces, with resultant impairment in gas exchange. The clinical course can be variable, ranging from spontaneous resolution to respiratory failure and death. PAP in all forms is caused by excessive accumulation of surfactant within the alveolar spaces. Autoimmune PAP accounts for the vast majority of cases in humans and is caused by autoantibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF), which results in impaired catabolism and clearance of surfactant lipids and proteins. Inherited or congenital forms of PAP are exceptionally rare and caused by mutations of genes encoding for surfactant proteins. Secondary forms of PAP are associated with diverse clinical disorders and are caused by reduced alveolar macrophage numbers or function with resultant reduced pulmonary clearance of surfactant. PAP is characterized by progressive exertional dyspnea and nonproductive cough with hypoxemia. Bilateral infiltrates are typically present on chest radiograph, and high-resolution computed tomography reveals diffuse ground-glass opacities and airspace consolidation with interlobular septal thickening in a characteristic “crazy paving” pattern. Although surgical lung biopsy will provide a definitive diagnosis, a combination of typical clinical and imaging features with periodic acid-Schiff (PAS)-positive material on bronchoalveolar lavage and transbronchial biopsies is usually sufficient. The standard of care for treatment of PAP remains whole lung lavage, but treatment is not required in all patients. Autoimmune PAP has also been successfully treated with GM-CSF, both inhaled and systemic, but the optimal dose, duration, and route of administration of GM-CSF have not been elucidated.

• References

• 1 Rosen SH, Castleman B, Liebow AA. Pulmonary alveolar proteinosis. N Engl J Med 1958; 258 (23) 1123-1142
  CrossrefPubMedGoogle Scholar
• 2 Trapnell BC, Whitsett JA, Nakata K. Pulmonary alveolar proteinosis. N Engl J Med 2003; 349 (26) 2527-2539
  CrossrefPubMedGoogle Scholar
• 3 Mazzone PJ, Jane Thomassen M, Kavuru MS. Pulmonary Alveolar Proteinosis: recent advances. Semin Respir Crit Care Med 2002; 23 (2) 115-126
  Article in Thieme ConnectPubMedGoogle Scholar
• 4 Shah PL, Hansell D, Lawson PR, Reid KB, Morgan C. Pulmonary alveolar proteinosis: clinical aspects and current concepts on pathogenesis. Thorax 2000; 55 (1) 67-77
  CrossrefPubMedGoogle Scholar
• 5 Ioachimescu OC, Kavuru MS. Pulmonary alveolar proteinosis. Chron Respir Dis 2006; 3 (3) 149-159
  CrossrefPubMedGoogle Scholar
• 6 Inoue Y, Trapnell BC, Tazawa R , et al; Japanese Center of the Rare Lung Diseases Consortium . Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan. Am J Respir Crit Care Med 2008; 177 (7) 752-762
  CrossrefPubMedGoogle Scholar
• 7 Xu Z, Jing J, Wang H, Xu F, Wang J. Pulmonary alveolar proteinosis in China: a systematic review of 241 cases. Respirology 2009; 14 (5) 761-766
  CrossrefPubMedGoogle Scholar
• 8 Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC. Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis 2010; 4 (4) 239-248
  CrossrefPubMedGoogle Scholar
• 9 Carey B, Trapnell BC. The molecular basis of pulmonary alveolar proteinosis. Clin Immunol 2010; 135 (2) 223-235
  CrossrefPubMedGoogle Scholar
• 10 Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002; 166 (2) 215-235
  CrossrefPubMedGoogle Scholar
• 11 Stanley E, Lieschke GJ, Grail D , et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci U S A 1994; 91 (12) 5592-5596
  CrossrefPubMedGoogle Scholar
• 12 Nishinakamura R, Nakayama N, Hirabayashi Y , et al. Mice deficient for the IL-3/GM-CSF/IL-5 beta c receptor exhibit lung pathology and impaired immune response, while beta IL3 receptor-deficient mice are normal. Immunity 1995; 2 (3) 211-222
  CrossrefPubMedGoogle Scholar
• 13 Robb L, Drinkwater CC, Metcalf D , et al. Hematopoietic and lung abnormalities in mice with a null mutation of the common beta subunit of the receptors for granulocyte-macrophage colony-stimulating factor and interleukins 3 and 5. Proc Natl Acad Sci U S A 1995; 92 (21) 9565-9569
  CrossrefPubMedGoogle Scholar
• 14 Seymour JF, Lieschke GJ, Grail D, Quilici C, Hodgson G, Dunn AR. Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival. Blood 1997; 90 (8) 3037-3049
  CrossrefPubMedGoogle Scholar
• 15 Kitamura T, Tanaka N, Watanabe J , et al. Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med 1999; 190 (6) 875-880
  CrossrefPubMedGoogle Scholar
• 16 Kitamura T, Uchida K, Tanaka N , et al. Serological diagnosis of idiopathic pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 162 (2 Pt 1) 658-662
  CrossrefPubMedGoogle Scholar
• 17 Carraway MS, Ghio AJ, Carter JD, Piantadosi CA. Detection of granulocyte-macrophage colony-stimulating factor in patients with pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161 (4 Pt 1) 1294-1299
  CrossrefPubMedGoogle Scholar
• 18 Bonfield TL, Russell D, Burgess S, Malur A, Kavuru MS, Thomassen MJ. Autoantibodies against granulocyte macrophage colony-stimulating factor are diagnostic for pulmonary alveolar proteinosis. Am J Respir Cell Mol Biol 2002; 27 (4) 481-486
  CrossrefPubMedGoogle Scholar
• 19 Lin FC, Chang GD, Chern MS, Chen YC, Chang SC. Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis. Thorax 2006; 61 (6) 528-534
  CrossrefPubMedGoogle Scholar
• 20 Nogee LM, de Mello DE, Dehner LP, Colten HR. Brief report: deficiency of pulmonary surfactant protein B in congenital alveolar proteinosis. N Engl J Med 1993; 328 (6) 406-410
  CrossrefPubMedGoogle Scholar
• 21 Nogee LM, Garnier G, Dietz HC , et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994; 93 (4) 1860-1863
  CrossrefPubMedGoogle Scholar
• 22 Lin Z, deMello DE, Wallot M, Floros J. An SP-B gene mutation responsible for SP-B deficiency in fatal congenital alveolar proteinosis: evidence for a mutation hotspot in exon 4. Mol Genet Metab 1998; 64 (1) 25-35
  CrossrefPubMedGoogle Scholar
• 23 Nogee LM. Alterations in SP-B and SP-C expression in neonatal lung disease. Annu Rev Physiol 2004; 66: 601-623
  CrossrefPubMedGoogle Scholar
• 24 Bullard JE, Wert SE, Whitsett JA, Dean M, Nogee LM. ABCA3 mutations associated with pediatric interstitial lung disease. Am J Respir Crit Care Med 2005; 172 (8) 1026-1031
  CrossrefPubMedGoogle Scholar
• 25 Brasch F, Schimanski S, Mühlfeld C , et al. Alteration of the pulmonary surfactant system in full-term infants with hereditary ABCA3 deficiency. Am J Respir Crit Care Med 2006; 174 (5) 571-580
  CrossrefPubMedGoogle Scholar
• 26 Deutsch GH, Young LR, Deterding RR , et al; Pathology Cooperative Group; ChILD Research Co-operative. Diffuse lung disease in young children: application of a novel classification scheme. Am J Respir Crit Care Med 2007; 176 (11) 1120-1128
  CrossrefPubMedGoogle Scholar
• 27 Doan ML, Guillerman RP, Dishop MK , et al. Clinical, radiological and pathological features of ABCA3 mutations in children. Thorax 2008; 63 (4) 366-373
  CrossrefPubMedGoogle Scholar
• 28 Suzuki T, Sakagami T, Rubin BK , et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008; 205 (12) 2703-2710
  CrossrefPubMedGoogle Scholar
• 29 Martinez-Moczygemba M, Doan ML, Elidemir O , et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008; 205 (12) 2711-2716
  CrossrefPubMedGoogle Scholar
• 30 Suzuki T, Sakagami T, Young LR , et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med 2010; 182 (10) 1292-1304
  CrossrefPubMedGoogle Scholar
• 31 Suzuki T, Maranda B, Sakagami T , et al. Hereditary pulmonary alveolar proteinosis caused by recessive CSF2RB mutations. Eur Respir J 2011; 37 (1) 201-204
  CrossrefPubMedGoogle Scholar
• 32 Ladeb S, Fleury-Feith J, Escudier E, Tran Van Nhieu J, Bernaudin JF, Cordonnier C. Secondary alveolar proteinosis in cancer patients. Support Care Cancer 1996; 4 (6) 420-426
  CrossrefPubMedGoogle Scholar
• 33 Ben-Dov I, Kishinevski Y, Roznman J , et al. Pulmonary alveolar proteinosis in Israel: ethnic clustering. Isr Med Assoc J 1999; 1 (2) 75-78
  PubMedGoogle Scholar
• 34 deMello DE, Lin Z. Pulmonary alveolar proteinosis: a review. Pediatr Pathol Mol Med 2001; 20 (5) 413-432
  CrossrefPubMedGoogle Scholar
• 35 Bonella F, Bauer PC, Griese M, Ohshimo S, Guzman J, Costabel U. Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med 2011; 105 (12) 1908-1916
  CrossrefPubMedGoogle Scholar
• 36 Mazzone P, Thomassen MJ, Kavuru M. Our new understanding of pulmonary alveolar proteinosis: what an internist needs to know. Cleve Clin J Med 2001; 68 (12) 977-978 , 981–982, 984–985 passim
  CrossrefPubMedGoogle Scholar
• 37 Presneill JJ, Nakata K, Inoue Y, Seymour JF. Pulmonary alveolar proteinosis. Clin Chest Med 2004; 25 (3) 593-613 , viii
  CrossrefPubMedGoogle Scholar
• 38 Lin FC, Chen YC, Chang HI, Chang SC. Effect of body position on gas exchange in patients with idiopathic pulmonary alveolar proteinosis: no benefit of prone positioning. Chest 2005; 127 (3) 1058-1064
  CrossrefPubMedGoogle Scholar
• 39 Bautin N, Fournier C, Marie E, Robin S, Neviere R, Wallaert B. Exercise performance of patients with alveolar proteinosis [in French]. Rev Mal Respir 2005; 22 (6 Pt 1) 943-950
  CrossrefPubMedGoogle Scholar
• 40 Nara M, Sano K, Ogawa H , et al. Serum antibody against granulocyte/macrophage colony-stimulating factor and KL-6 in idiopathic pulmonary alveolar proteinosis. Tohoku J Exp Med 2006; 208 (4) 349-354
  CrossrefPubMedGoogle Scholar
• 41 Inoue Y, Nakata K, Arai T , et al. Epidemiological and clinical features of idiopathic pulmonary alveolar proteinosis in Japan. Respirology 2006; 11 (Suppl) S55-S60
  CrossrefPubMedGoogle Scholar
• 42 Doyle IR, Bersten AD, Nicholas TE. Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure. Am J Respir Crit Care Med 1997; 156 (4 Pt 1) 1217-1229
  CrossrefPubMedGoogle Scholar
• 43 Honda Y, Kuroki Y, Shijubo N , et al. Aberrant appearance of lung surfactant protein A in sera of patients with idiopathic pulmonary fibrosis and its clinical significance. Respiration 1995; 62 (2) 64-69
  CrossrefPubMedGoogle Scholar
• 44 Honda Y, Kuroki Y, Matsuura E , et al. Pulmonary surfactant protein D in sera and bronchoalveolar lavage fluids. Am J Respir Crit Care Med 1995; 152 (6 Pt 1) 1860-1866
  CrossrefPubMedGoogle Scholar
• 45 Iyonaga K, Suga M, Yamamoto T, Ichiyasu H, Miyakawa H, Ando M. Elevated bronchoalveolar concentrations of MCP-1 in patients with pulmonary alveolar proteinosis. Eur Respir J 1999; 14 (2) 383-389
  PubMedGoogle Scholar
• 46 Kavuru MS, Sullivan EJ, Piccin R, Thomassen MJ, Stoller JK. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2000; 161 (4 Pt 1) 1143-1148
  CrossrefPubMedGoogle Scholar
• 47 Huizar I, Kavuru MS. Alveolar proteinosis syndrome: pathogenesis, diagnosis, and management. Curr Opin Pulm Med 2009; 15 (5) 491-498
  CrossrefPubMedGoogle Scholar
• 48 Holbert JM, Costello P, Li W, Hoffman RM, Rogers RM. CT features of pulmonary alveolar proteinosis. AJR Am J Roentgenol 2001; 176 (5) 1287-1294
  CrossrefPubMedGoogle Scholar
• 49 Chung MJ, Lee KS, Franquet T, Müller NL, Han J, Kwon OJ. Metabolic lung disease: imaging and histopathologic findings. Eur J Radiol 2005; 54 (2) 233-245
  CrossrefPubMedGoogle Scholar
• 50 Ishii H, Trapnell BC, Tazawa R , et al; Japanese Center of the Rare Lung Disease Consortium. Comparative study of high-resolution CT findings between autoimmune and secondary pulmonary alveolar proteinosis. Chest 2009; 136 (5) 1348-1355
  CrossrefPubMedGoogle Scholar
• 51 Singh G, Katyal SL, Bedrossian CW, Rogers RM. Pulmonary alveolar proteinosis. Staining for surfactant apoprotein in alveolar proteinosis and in conditions simulating it. Chest 1983; 83 (1) 82-86
  CrossrefPubMedGoogle Scholar
• 52 Chou CW, Lin FC, Tung SM, Liou RD, Chang SC. Diagnosis of pulmonary alveolar proteinosis: usefulness of papanicolaou-stained smears of bronchoalveolar lavage fluid. Arch Intern Med 2001; 161 (4) 562-566
  CrossrefPubMedGoogle Scholar
• 53 Martínez-López MA, Gómez-Cerezo G, Villasante C , et al. Pulmonary alveolar proteinosis: prolonged spontaneous remission in two patients. Eur Respir J 1991; 4 (3) 377-379
  PubMedGoogle Scholar
• 54 Witty LA, Tapson VF, Piantadosi CA. Isolation of mycobacteria in patients with pulmonary alveolar proteinosis. Medicine (Baltimore) 1994; 73 (2) 103-109
  CrossrefPubMedGoogle Scholar
• 55 Oerlemans WG, Jansen EN, Prevo RL, Eijsvogel MM. Primary cerebellar nocardiosis and alveolar proteinosis. Acta Neurol Scand 1998; 97 (2) 138-141
  PubMedGoogle Scholar
• 56 Su KC, Lay SL, Perng RP, Chang SC, Chen YM. Lung cancer may develop subsequently or coincidently with pulmonary alveolar proteinosis. Lung Cancer 2007; 58 (1) 144-148
  CrossrefPubMedGoogle Scholar
• 57 Takahashi H, Sano H, Chiba H, Kuroki Y. Pulmonary surfactant proteins A and D: innate immune functions and biomarkers for lung diseases. Curr Pharm Des 2006; 12 (5) 589-598
  CrossrefPubMedGoogle Scholar
• 58 Brasch F, Birzele J, Ochs M , et al. Surfactant proteins in pulmonary alveolar proteinosis in adults. Eur Respir J 2004; 24 (3) 426-435
  CrossrefPubMedGoogle Scholar
• 59 Doyle IR, Davidson KG, Barr HA, Nicholas TE, Payne K, Pfitzner J. Quantity and structure of surfactant proteins vary among patients with alveolar proteinosis. Am J Respir Crit Care Med 1998; 157 (2) 658-664
  CrossrefPubMedGoogle Scholar
• 60 Dranoff G, Crawford AD, Sadelain M , et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science 1994; 264 (5159) 713-716
  CrossrefPubMedGoogle Scholar
• 61 Scott CL, Hughes DA, Cary D, Nicola NA, Begley CG, Robb L. Functional analysis of mature hematopoietic cells from mice lacking the betac chain of the granulocyte-macrophage colony-stimulating factor receptor. Blood 1998; 92 (11) 4119-4127
  PubMedGoogle Scholar
• 62 Zhan Y, Lieschke GJ, Grail D, Dunn AR, Cheers C. Essential roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenes-infected mice. Blood 1998; 91 (3) 863-869
  CrossrefPubMedGoogle Scholar
• 63 Wada H, Noguchi Y, Marino MW, Dunn AR, Old LJ. T cell functions in granulocyte/macrophage colony-stimulating factor deficient mice. Proc Natl Acad Sci U S A 1997; 94 (23) 12557-12561
  CrossrefPubMedGoogle Scholar
• 64 Ikegami M, Ueda T, Hull W , et al. Surfactant metabolism in transgenic mice after granulocyte macrophage-colony stimulating factor ablation. Am J Physiol 1996; 270 (4 Pt 1) L650-L658
  PubMedGoogle Scholar
• 65 Reed JA, Ikegami M, Cianciolo ER , et al. Aerosolized GM-CSF ameliorates pulmonary alveolar proteinosis in GM-CSF-deficient mice. Am J Physiol 1999; 276 (4 Pt 1) L556-L563
  PubMedGoogle Scholar
• 66 Huffman JA, Hull WM, Dranoff G, Mulligan RC, Whitsett JA. Pulmonary epithelial cell expression of GM-CSF corrects the alveolar proteinosis in GM-CSF-deficient mice. J Clin Invest 1996; 97 (3) 649-655
  CrossrefPubMedGoogle Scholar
• 67 Nishinakamura R, Wiler R, Dirksen U , et al. The pulmonary alveolar proteinosis in granulocyte macrophage colony-stimulating factor/interleukins 3/5 beta c receptor-deficient mice is reversed by bone marrow transplantation. J Exp Med 1996; 183 (6) 2657-2662
  CrossrefPubMedGoogle Scholar
• 68 Cooke KR, Nishinakamura R, Martin TR , et al. Persistence of pulmonary pathology and abnormal lung function in IL-3/GM-CSF/IL-5 beta c receptor-deficient mice despite correction of alveolar proteinosis after BMT. Bone Marrow Transplant 1997; 20 (8) 657-662
  CrossrefPubMedGoogle Scholar
• 69 Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasaki S, Nakata K. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett 1999; 442 (2-3) 246-250
  CrossrefPubMedGoogle Scholar
• 70 Thomassen MJ, Yi T, Raychaudhuri B, Malur A, Kavuru MS. Pulmonary alveolar proteinosis is a disease of decreased availability of GM-CSF rather than an intrinsic cellular defect. Clin Immunol 2000; 95 (2) 85-92
  CrossrefPubMedGoogle Scholar
• 71 Bewig B, Wang XD, Kirsten D, Dalhoff K, Schäfer HGM-CSF. GM-CSF and GM-CSF beta c receptor in adult patients with pulmonary alveolar proteinosis. Eur Respir J 2000; 15 (2) 350-357
  CrossrefPubMedGoogle Scholar
• 72 Seymour JF, Presneill JJ, Schoch OD , et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med 2001; 163 (2) 524-531
  CrossrefPubMedGoogle Scholar
• 73 Uchida K, Nakata K, Trapnell BC , et al. High-affinity autoantibodies specifically eliminate granulocyte-macrophage colony-stimulating factor activity in the lungs of patients with idiopathic pulmonary alveolar proteinosis. Blood 2004; 103 (3) 1089-1098
  PubMedGoogle Scholar
• 74 Seymour JF, Dunn AR, Vincent JM, Presneill JJ, Pain MC. Efficacy of granulocyte-macrophage colony-stimulating factor in acquired alveolar proteinosis. N Engl J Med 1996; 335 (25) 1924-1925
  CrossrefPubMedGoogle Scholar
• 75 Sakagami T, Uchida K, Suzuki T , et al. Human GM-CSF autoantibodies and reproduction of pulmonary alveolar proteinosis. N Engl J Med 2009; 361 (27) 2679-2681
  CrossrefPubMedGoogle Scholar
• 76 Bonfield TL, Raychaudhuri B, Malur A , et al. PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor. Am J Physiol Lung Cell Mol Physiol 2003; 285 (5) L1132-L1136
  CrossrefPubMedGoogle Scholar
• 77 Trapnell BC, Whitsett JA. Gm-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. Annu Rev Physiol 2002; 64: 775-802
  CrossrefPubMedGoogle Scholar
• 78 Nakata K, Kanazawa H, Watanabe M. Why does the autoantibody against granulocyte-macrophage colony-stimulating factor cause lesions only in the lung?. Respirology 2006; 11 (Suppl) S65-S69
  CrossrefPubMedGoogle Scholar
• 79 Uchida K, Beck DC, Yamamoto T , et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007; 356 (6) 567-579
  CrossrefPubMedGoogle Scholar
• 80 Gonzalez-Rothi RJ, Harris JO. Pulmonary alveolar proteinosis. Further evaluation of abnormal alveolar macrophages. Chest 1986; 90 (5) 656-661
  CrossrefPubMedGoogle Scholar
• 81 Seymour JF. Extra-pulmonary aspects of acquired pulmonary alveolar proteinosis as predicted by granulocyte-macrophage colony-stimulating factor-deficient mice. Respirology 2006; 11 (Suppl) S16-S22
  CrossrefPubMedGoogle Scholar
• 82 Nogee LM, Wert SE, Proffit SA, Hull WM, Whitsett JA. Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am J Respir Crit Care Med 2000; 161 (3 Pt 1) 973-981
  CrossrefPubMedGoogle Scholar
• 83 Thouvenin G, Abou Taam R, Flamein F , et al. Characteristics of disorders associated with genetic mutations of surfactant protein C. Arch Dis Child 2010; 95 (6) 449-454
  CrossrefPubMedGoogle Scholar
• 84 Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N Engl J Med 2004; 350 (13) 1296-1303
  CrossrefPubMedGoogle Scholar
• 85 Tanaka T, Motoi N, Tsuchihashi Y , et al. Adult-onset hereditary pulmonary alveolar proteinosis caused by a single-base deletion in CSF2RB. J Med Genet 2011; 48 (3) 205-209
  CrossrefPubMedGoogle Scholar
• 86 Cordonnier C, Fleury-Feith J, Escudier E, Atassi K, Bernaudin JF. Secondary alveolar proteinosis is a reversible cause of respiratory failure in leukemic patients. Am J Respir Crit Care Med 1994; 149 (3 Pt 1) 788-794
  CrossrefPubMedGoogle Scholar
• 87 Dirksen U, Hattenhorst U, Schneider P , et al. Defective expression of granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 receptor common beta chain in children with acute myeloid leukemia associated with respiratory failure. Blood 1998; 92 (4) 1097-1103
  PubMedGoogle Scholar
• 88 Shoji N, Ito Y, Kimura Y , et al. Pulmonary alveolar proteinosis as a terminal complication in myelodysplastic syndromes: a report of four cases detected on autopsy. Leuk Res 2002; 26 (6) 591-595
  CrossrefPubMedGoogle Scholar
• 89 Pamuk GE, Turgut B, Vural O , et al. Pulmonary alveolar proteinosis in a patient with acute lymphoid leukemia regression after G-CSF therapy. Leuk Lymphoma 2003; 44 (5) 871-874
  CrossrefPubMedGoogle Scholar
• 90 Sergeeva A, Ono Y, Rios R, Molldrem JJ. High titer autoantibodies to GM-CSF in patients with AML, CML and MDS are associated with active disease. Leukemia 2008; 22 (4) 783-790
  CrossrefPubMedGoogle Scholar
• 91 Grunebaum E, Cutz E, Roifman CM. Pulmonary alveolar proteinosis in patients with adenosine deaminase deficiency. J Allergy Clin Immunol 2012; 129 (6) 1588-1593
  CrossrefPubMedGoogle Scholar
• 92 Patiroglu T, Akyildiz B, Patiroglu TE, Gulmez IY. Recurrent pulmonary alveolar proteinosis secondary to agammaglobulinemia. Pediatr Pulmonol 2008; 43 (7) 710-713
  CrossrefPubMedGoogle Scholar
• 93 Tran Van Nhieu J, Vojtek AM, Bernaudin JF, Escudier E, Fleury-Feith J. Pulmonary alveolar proteinosis associated with Pneumocystis carinii: ultrastructural identification in bronchoalveolar lavage in AIDS and immunocompromised non-AIDS patients. Chest 1990; 98 (4) 801-805
  CrossrefPubMedGoogle Scholar
• 94 Santamaria F, Brancaccio G, Parenti G , et al. Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance. J Pediatr 2004; 145 (2) 268-272
  PubMedGoogle Scholar
• 95 Samuels MP, Warner JO. Pulmonary alveolar lipoproteinosis complicating juvenile dermatomyositis. Thorax 1988; 43 (11) 939-940
  CrossrefPubMedGoogle Scholar
• 96 Yousem SA. Alveolar lipoproteinosis in lung allograft recipients. Hum Pathol 1997; 28 (12) 1383-1386
  CrossrefPubMedGoogle Scholar
• 97 Kadikoy H, Paolini M, Achkar K , et al. Pulmonary alveolar proteinosis in a kidney transplant: a rare complication of sirolimus. Nephrol Dial Transplant 2010; 25 (8) 2795-2798
  CrossrefPubMedGoogle Scholar
• 98 Wardwell Jr NR, Miller R, Ware LB. Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug. Respirology 2006; 11 (5) 663-665
  CrossrefPubMedGoogle Scholar
• 99 Hosokawa T, Yamaguchi E, Shirai S , et al. A case of idiopathic pulmonary alveolar proteinosis accompanied by T-cell receptor gene rearrangement in bronchoalveolar lavage fluid cells. Respirology 2004; 9 (2) 286-288
  CrossrefPubMedGoogle Scholar
• 100 Marchiori E, Souza CA, Barbassa TG, Escuissato DL, Gasparetto EL, Souza Jr AS. Silicoproteinosis: high-resolution CT findings in 13 patients. AJR Am J Roentgenol 2007; 189 (6) 1402-1406
  CrossrefPubMedGoogle Scholar
• 101 McCunney RJ, Godefroi R. Pulmonary alveolar proteinosis and cement dust: a case report. J Occup Med 1989; 31 (3) 233-237
  CrossrefPubMedGoogle Scholar
• 102 McDonald JW, Alvarez F, Keller CA. Pulmonary alveolar proteinosis in association with household exposure to fibrous insulation material. Chest 2000; 117 (6) 1813-1817
  CrossrefPubMedGoogle Scholar
• 103 Keller CA, Frost A, Cagle PT, Abraham JL. Pulmonary alveolar proteinosis in a painter with elevated pulmonary concentrations of titanium. Chest 1995; 108 (1) 277-280
  CrossrefPubMedGoogle Scholar
• 104 Miller RR, Churg AM, Hutcheon M, Lom S. Pulmonary alveolar proteinosis and aluminum dust exposure. Am Rev Respir Dis 1984; 130 (2) 312-315
  PubMedGoogle Scholar
• 105 Cummings KJ, Donat WE, Ettensohn DB, Roggli VL, Ingram P, Kreiss K. Pulmonary alveolar proteinosis in workers at an indium processing facility. Am J Respir Crit Care Med 2010; 181 (5) 458-464
  CrossrefPubMedGoogle Scholar
• 106 Dawkins SA, Gerhard H, Nevin M. Pulmonary alveolar proteinosis: a possible sequel of NO2 exposure. J Occup Med 1991; 33 (5) 638-641
  PubMedGoogle Scholar
• 107 Michaud G, Reddy C, Ernst A. Whole-lung lavage for pulmonary alveolar proteinosis. Chest 2009; 136 (6) 1678-1681
  CrossrefPubMedGoogle Scholar
• 108 Kavuru MS, Popovich M. Therapeutic whole lung lavage: a stop-gap therapy for alveolar proteinosis. Chest 2002; 122 (4) 1123-1124
  CrossrefPubMedGoogle Scholar
• 109 Perez IV A, Rogers RM. Enhanced alveolar clearance with chest percussion therapy and positional changes during whole-lung lavage for alveolar proteinosis. Chest 2004; 125 (6) 2351-2356
  CrossrefPubMedGoogle Scholar
• 110 Menard KJ. Whole lung lavage in the treatment of pulmonary alveolar proteinosis. J Perianesth Nurs 2005; 20 (2) 114-126
  CrossrefPubMedGoogle Scholar
• 111 Prakash UB, Barham SS, Carpenter HA, Dines DE, Marsh HM. Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc 1987; 62 (6) 499-518
  CrossrefPubMedGoogle Scholar
• 112 Beccaria M, Luisetti M, Rodi G , et al. Long-term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J 2004; 23 (4) 526-531
  CrossrefPubMedGoogle Scholar
• 113 Seymour JF, Doyle IR, Nakata K , et al. Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis. Thorax 2003; 58 (3) 252-257
  CrossrefPubMedGoogle Scholar
• 114 Schoch OD, Schanz U, Koller M , et al. BAL findings in a patient with pulmonary alveolar proteinosis successfully treated with GM-CSF. Thorax 2002; 57 (3) 277-280
  CrossrefPubMedGoogle Scholar
• 115 Barraclough RM, Gillies AJ. Pulmonary alveolar proteinosis: a complete response to GM-CSF therapy. Thorax 2001; 56 (8) 664-665
  CrossrefPubMedGoogle Scholar
• 116 de Vega MG, Sánchez-Palencia A, Ramírez A, Cervera S, Aneiros J. GM-CSF therapy in pulmonary alveolar proteinosis. Thorax 2002; 57 (9) 837
  CrossrefPubMedGoogle Scholar
• 117 Khanjari F, Watier H, Domenech J, Asquier E, Diot P, Nakata K. GM-CSF and proteinosis. Thorax 2003; 58 (7) 645
  CrossrefPubMedGoogle Scholar
• 118 Abdul Rahman JA, Moodley YP, Phillips MJ. Pulmonary alveolar proteinosis associated with psoriasis and complicated by mycobacterial infection: successful treatment with granulocyte-macrophage colony stimulating factor after a partial response to whole lung lavage. Respirology 2004; 9 (3) 419-422
  CrossrefPubMedGoogle Scholar
• 119 Bonfield TL, Kavuru MS, Thomassen MJ. Anti-GM-CSF titer predicts response to GM-CSF therapy in pulmonary alveolar proteinosis. Clin Immunol 2002; 105 (3) 342-350
  CrossrefPubMedGoogle Scholar
• 120 Venkateshiah SB, Yan TD, Bonfield TL , et al. An open-label trial of granulocyte macrophage colony stimulating factor therapy for moderate symptomatic pulmonary alveolar proteinosis. Chest 2006; 130 (1) 227-237
  CrossrefPubMedGoogle Scholar
• 121 Venkateshiah SB, Thomassen MJ, Kavuru MS. Pulmonary alveolar proteinosis: clinical manifestations and optimal treatment strategies. Treat Respir Med 2004; 3 (4) 217-227
  CrossrefPubMedGoogle Scholar
• 122 Tazawa R, Hamano E, Arai T , et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2005; 171 (10) 1142-1149
  CrossrefPubMedGoogle Scholar
• 123 Kavuru MS, Bonfield TL, Thomassen MJ. Plasmapheresis, GM-CSF, and alveolar proteinosis. Am J Respir Crit Care Med 2003; 167 (7) 1036 , author reply 1036–1037
  CrossrefPubMedGoogle Scholar
• 124 Wylam ME, Ten R, Prakash UB, Nadrous HF, Clawson ML, Anderson PM. Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis. Eur Respir J 2006; 27 (3) 585-593
  CrossrefPubMedGoogle Scholar
• 125 Arai T, Hamano E, Inoue Y , et al. Serum neutralizing capacity of GM-CSF reflects disease severity in a patient with pulmonary alveolar proteinosis successfully treated with inhaled GM-CSF. Respir Med 2004; 98 (12) 1227-1230
  CrossrefPubMedGoogle Scholar
• 126 Tazawa R, Trapnell BC, Inoue Y , et al. Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis. Am J Respir Crit Care Med 2010; 181 (12) 1345-1354
  CrossrefPubMedGoogle Scholar
• 127 Sihoe AD, Ng VM, Liu RW, Cheng LC. Pulmonary alveolar proteinosis in extremis: the case for aggressive whole lung lavage with extracorporeal membrane oxygenation support. Heart Lung Circ 2008; 17 (1) 69-72
  CrossrefPubMedGoogle Scholar
• 128 Sivitanidis E, Tosson R, Wiebalck A, Laczkovics A. Combination of extracorporeal membrane oxygenation (ECMO) and pulmonary lavage in a patient with pulmonary alveolar proteinosis. Eur J Cardiothorac Surg 1999; 15 (3) 370-372
  CrossrefPubMedGoogle Scholar
• 129 Luisetti M, Rodi G, Perotti C , et al. Plasmapheresis for treatment of pulmonary alveolar proteinosis. Eur Respir J 2009; 33 (5) 1220-1222
  CrossrefPubMedGoogle Scholar
• 130 Robertson HE. Pulmonary alveolar proteinosis. Can Med Assoc J 1965; 93 (18) 980-983
  PubMedGoogle Scholar
• 131 Borie R, Debray MP, Laine C, Aubier M, Crestani B. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J 2009; 33 (6) 1503-1506
  CrossrefPubMedGoogle Scholar
• 132 Kavuru MS, Malur A, Marshall I , et al. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J 2011; 38 (6) 1361-1367
  CrossrefPubMedGoogle Scholar
• 133 Amital A, Dux S, Shitrit D, Shpilberg O, Kramer MR. Therapeutic effectiveness of rituximab in a patient with unresponsive autoimmune pulmonary alveolar proteinosis. Thorax 2010; 65 (11) 1025-1026
  CrossrefPubMedGoogle Scholar
• 134 Parker LA, Novotny DB. Recurrent alveolar proteinosis following double lung transplantation. Chest 1997; 111 (5) 1457-1458
  CrossrefPubMedGoogle Scholar
• 135 Hamvas A, Nogee LM, Mallory Jr GB , et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr 1997; 130 (2) 231-239
  CrossrefPubMedGoogle Scholar
• 136 Gal AA, Bryan JA, Kanter KR, Lawrence EC. Cytopathology of pulmonary alveolar proteinosis complicating lung transplantation. J Heart Lung Transplant 2004; 23 (1) 135-138
  CrossrefPubMedGoogle Scholar
• 137 Du EZ, Yung GL, Le DT, Masliah E, Yi ES, Friedman PJ. Severe alveolar proteinosis following chemotherapy for acute myeloid leukemia in a lung allograft recipient. J Thorac Imaging 2001; 16 (4) 307-309
  CrossrefPubMedGoogle Scholar